Xenetic Biosciences Extends Partnership with Scripps to Boost DNase Oncology Program

Xenetic Biosciences, Inc. has announced an extension of its collaboration with The Scripps Research Institute to advance its DNase oncology platform. The company's DNase I candidate is under preclinical evaluation combined with CAR T-cell therapies, targeting hematological cancers and metastatic melanoma. Prior studies have indicated that DNase I enhances CAR T-cell therapy by reducing tumor burden and enhancing immune response.

This initiative focuses on degrading neutrophil extracellular traps (NETs), structures that contribute to cancer spread. Xenetic aims to incorporate DNase I as an adjunctive treatment to improve therapeutic responses in CAR T-cell therapies. The collaboration with Scripps also offers Xenetic the option to acquire licenses for new intellectual property emerging from the DNase research.

The company's strategy is oriented towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other tumors. The extension of the research agreement signifies Xenetic's commitment to leveraging cutting-edge science to enhance cancer treatment.